Integrated BioPharma (INBP) AI Stock Analysis

• Market Cap: $9.86M
• Dividend Yield: N/A
• Average Volume (3M): 27.69K
• Price to Earnings (P/E): 8.1
• Beta (1Y): 0.54
• Revenue Growth: 4.67%
• EPS Growth: N/A
• Country: US
• Employees: 147
• Sector: Healthcare
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): 0.02
• Shares Outstanding: 30,300,720
• 10 Day Avg. Volume: 31,368
• 30 Day Avg. Volume: 27,689
• PEG Ratio: 2.88
• Price to Book (P/B): 0.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 8.86
• Enterprise Value/Market Cap: 1.14
• Enterprise Value/Revenue: 0.05
• Enterprise Value/Gross Profit: 2.09
• Enterprise Value/Ebitda: 1.45
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 77 Outperform
• Price Target: $0.50 ▲(56.25%Upside)

Integrated BioPharma's strong financial performance and positive corporate event with the new credit line are significant strengths. The technical analysis shows positive momentum, although caution is advised due to potential overbought conditions. Valuation metrics suggest the stock is undervalued, providing a favorable investment opportunity despite no dividend yield. Overall, the company is well-positioned for stability and potential growth.

Integrated BioPharma Business Overview & Revenue Model

Company Description

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized healthcare providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

How the Company Makes Money

Integrated BioPharma primarily generates revenue through the sale of its nutraceutical and pharmaceutical products. The company has established a diverse revenue model, which includes direct sales to consumers, distribution through retail partners, and partnerships with major health and wellness brands. Additionally, Integrated BioPharma engages in contract manufacturing, producing private-label products for other companies, thus diversifying its income streams. The company’s revenue is further supported by strategic collaborations and partnerships that enhance its market reach and operational efficiency.

Integrated BioPharma Financial Statement Overview

Summary

Integrated BioPharma demonstrates a balanced financial position with strong cash flow and low leverage, which are significant strengths. However, challenges remain with declining revenue and moderate profitability, reflected in income statement metrics. The company is well-positioned with its solid balance sheet and robust cash flow, providing a foundation for future growth and stability.

Income Statement

Integrated BioPharma's income statement shows a declining revenue trend from 2021 to 2024, with a recent TTM revenue of $52.93M, down from $53.17M annually. The company's gross profit margin stands at 9.59%, and a net profit margin of 1.75% for TTM indicates modest profitability, although improved from previous years. The EBIT margin of 2.74% and EBITDA margin of 3.34% demonstrate operational efficiency improvement over the past reporting periods. However, the decline in revenue growth presents a concern.

Balance Sheet

The balance sheet reflects strong financial health with a debt-to-equity ratio of 0.07, indicating low leverage. The equity ratio of 76.89% in the TTM period shows a strong equity base relative to assets. Return on equity is modest at 4.71%, suggesting limited profitability relative to equity. The company's stable equity position and low debt enhance its financial stability, though ROE could be improved.

Cash Flow

Cash flow analysis shows positive trends with a free cash flow growth rate of 345.64% from the previous annual report to the TTM. The operating cash flow to net income ratio is 2.49, and the free cash flow to net income ratio is 1.87, indicating strong cash conversion from profits. Consistent free cash flow generation supports operational sustainability and investment capabilities.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	52.92M	50.32M	50.67M	56.25M	63.56M	52.77M
Gross Profit	5.38M	3.88M	4.06M	6.55M	9.48M	6.73M
EBITDA	3.08M	1.54M	1.27M	3.56M	8.33M	4.26M
Net Income	1.25M	112.00K	-34.00K	3.84M	8.01M	4.11M
Balance Sheet
Total Assets	25.66M	26.21M	25.43M	25.25M	25.44M	22.94M
Cash, Cash Equivalents and Short-Term Investments	2.96M	1.68M	1.32M	331.00K	210.00K	402.00K
Total Debt	1.14M	1.80M	2.67M	2.06M	6.00M	11.13M
Total Liabilities	5.27M	6.97M	6.57M	6.67M	11.11M	16.88M
Stockholders Equity	20.38M	19.24M	18.86M	18.57M	14.33M	6.07M
Cash Flow
Free Cash Flow	941.00K	390.00K	1.12M	3.60M	2.75M	1.13M
Operating Cash Flow	1.29M	943.00K	1.23M	4.09M	3.05M	1.34M
Investing Cash Flow	-347.00K	-553.00K	-111.00K	-465.00K	-199.00K	-110.00K
Financing Cash Flow	0.00	-29.00K	-136.00K	-3.50M	-3.04M	-1.30M

Integrated BioPharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBP, the sentiment is Positive. The current price of 0.32 is above the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.30, and above the 200-day MA of 0.30, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 51.20 is Neutral, neither overbought nor oversold. The STOCH value of 80.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INBP.

Integrated BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INBP	77 Outperform	$9.86M	8.06	6.38%	―	4.67%	―
NATR	77 Outperform	$267.72M	27.09	6.42%	―	2.00%	-37.09%
USNA	72 Outperform	$579.74M	17.05	6.78%	―	-2.69%	-43.24%
FTLF	72 Outperform	$120.30M	14.11	25.89%	―	9.14%	18.87%
HLF	71 Outperform	$889.12M	3.18	-31.74%	―	-2.45%	100.59%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	16.99%	1.69%
NAII	47 Neutral	$19.90M	―	-10.25%	―	-1.16%	-146.23%

Integrated BioPharma Corporate Events

Integrated BioPharma Secures New Credit Line with PNC

On April 15, 2025, Integrated BioPharma, Inc. and its subsidiary, Manhattan Drug Company, entered into a Loan Agreement with PNC Bank, securing a revolving line of credit of up to $4 million and a Convertible Equipment Line of Credit of up to $500,000. This agreement, which includes a security interest in the company’s assets, aims to support the purchase of equipment and vehicles. Concurrently, Integrated BioPharma and its associated entities settled their previous credit and loan agreement with PNC Bank, paying off the outstanding balance and terminating the prior arrangement, marking a strategic financial restructuring.